GlaxoSmithKline LLC can’t be held liable to plaintiffs who alleged generic versions of its anti-nausea drug Zofran caused birth defects, a federal court held (In re Zofran (Ondansetron) Prod. Liab. Litig., D. Mass., No. 15-2657, 8/4/17).
The U.S. District Court for the District of Massachusetts dismissed six suits against the drugmaker filed by plaintiffs from Georgia, Indiana, Kentucky, Massachusetts, New York, and Oklahoma. The court oversees a combined federal court Zofran proceeding.
Plaintiffs alleged Zofran, approved to treat nausea associated with chemotherapy, was widely promoted to treat pregnancy-related sickness, an off-label or unapproved use.
An estimated 20 percent ...
Learn more about Bloomberg Law or Log In to keep reading:
See Breaking News in Context
Bloomberg Law provides trusted coverage of current events enhanced with legal analysis.
Already a subscriber?
Log in to keep reading or access research tools and resources.